Syngenta is ending paraquat sales in Australia after the national regulator imposed new restrictions on the controversial herbicide. The company said its exit from the paraquat market in Australia and New Zealand followed the Australian Pesticides and Veterinary Medicines Authority's limit changes and its own commercial review. Farmers and growers are left to deal with the fallout while the machinery of regulation and corporate retreat sorts itself out above their heads.
Who Gets the Bill
The APVMA introduced new limits and conditions on how paraquat can be used last month. The regulator found no evidence the chemical increased the risk of Parkinson's disease if used safely with the authority's significant restrictions in place. It stopped short of an outright ban. That leaves the product in circulation, but under tighter control from a regulator that has chosen restriction over removal.
In a statement released on Friday, Syngenta ANZ said: "Regulatory constraints, combined with a highly complex and increasingly expensive supply chain, have made the paraquat herbicide products commercially unviable," managing director David Van Ryswyk said. The language is pure corporate arithmetic. If the numbers don't work, the product goes. The people who use it don't get a vote in that calculation.
What the Company Calls 'Difficult'
In March, Syngenta announced plans to end production of paraquat at its UK plant, ceasing global production by the end of June. At the time, the company confirmed a commitment to supplying Australian farmers via a third-party manufacturer. That arrangement is now ending as well. The supply line narrows, then disappears, and the market is told to adjust.
"Dedicating significant resources to unprofitable legacy products is no longer sustainable," Mr Van Ryswyk said. "Paraquat has been a highly valued productivity and conservation tool for many Australian and New Zealand growers. This decision, while difficult, allows us to redirect our resources," he said. The company frames withdrawal as prudence. The growers who relied on the product get a lesson in how fragile corporate promises really are.
Generic versions of paraquat will still be sold in Australia by other companies. Western Victorian farmer and Grain Producers Australia spokesman Andrew Weidemann said Syngenta's exit created uncertainty. "Syngenta has been the stable foundation of this market for decades," he said. Mr Weidemann said there are many other paraquat chemicals available, but "unfortunately, most of them [are] coming out of China". "[Syngenta's] withdrawal leaves some important questions about what happens next," he said.
The Industry Pays, the Regulator Watches
Mr Weidemann said he was concerned Syngenta's decision would make label changes required by the APVMA more difficult. "Some of the changes in grams active and the withholding periods on late applications in crop, that work will fall clearly on the feet of the industry," he said. "So it's going to be a cost and … that's going to be something that we as the industry will have to work through."
That is the hierarchy in plain sight. The regulator sets the conditions. The company decides what's worth selling. The industry absorbs the cost. The people at the bottom are expected to adapt, pay up, and keep the system moving.
Syngenta said it would manage the phase-out of its paraquat products in strict alignment with the APVMA's designated sell-out and use-by timelines. In a statement, the APVMA said it does not comment on the commercial decisions of individual companies. The regulator writes the rules, the corporation follows the profitable path, and the public gets the leftovers of that arrangement.
The APVMA found no evidence the chemical increased the risk of Parkinson's disease if used safely with the authority's significant restrictions in place, but it still imposed new limits and conditions last month. No outright ban. Just another managed compromise, with the burden of compliance pushed downward and the commercial exit handled upward. The market keeps moving. The growers keep adjusting. The institutions keep talking about safety, viability, and timelines while ordinary people live with the consequences.